Typical and atypical antipsychotics in bipolar depression

Journal of Clinical Psychiatry

Volumn 66, Issue 11, 2005, Pages 1376-1385

  Gao, Keming ^a,b   Gajwani, Prashant ^a   Elhaj, Omar ^a   Calabrese, Joseph R ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b Mood Disorders Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUOXETINE; FLUPENTIXOL; FLUPENTIXOL DECANOATE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADD ON THERAPY; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; DISEASE EXACERBATION; HUMAN; MAINTENANCE THERAPY; MEDICAL LITERATURE; MONOTHERAPY; PEER REVIEW; PRIORITY JOURNAL; RAPID CYCLING BIPOLAR DISORDER; RELAPSE; TREATMENT OUTCOME;

EID: 28844471630     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n1106     Document Type: Article

References (78)

1. Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-1442
2. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537
3. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003;64:680-690
4. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261-269
5. Calabrese JR, Hirschfeld RMA, Frye MA, et al. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a US community-based sample. J Clin Psychiatry 2004;65:1499-1504
6. MacQueen GM, Young LT, Joffe RT. A review of psychosocial outcome in patients with bipolar disorder. Acta Psychiatr Scand 2001;103:163-170
7. MacQueen GM, Young LT, Robb JC, et al. Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. Acta Psychiatr Scand 2000;101:374-381
8. Goodwin F, Jamison K. Manie-Depressive Illness. New York, NY: Oxford University Press; 1990
9. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997;170:205-228
10. Dilsaver SC, Chen YW, Swann AC, et al. Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania. Psychiatry Res 1997;73:47-56
11. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Bipolar Disorder [Revision]. Am J Psychiatry 2002;159 (suppl 4):1-50
12. Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003;17:149-173
13. Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993;13:397-408
14. Maj M. The impact of lithium prophylaxis on the course of bipolar disorder: a review of the research evidence. Bipolar Disord 2000;2:93-101
15. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999;60:79-88
16. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000;61:841-850
17. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607-614
18. Calabrese JR, Bowden CL, Sachs GS, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:1013-1024
19. Bowden CL, Calabrese JR, Sachs GS, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic and hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400
20. Shopsin B, Gershon S, Thompson H, et al. Psychoactive drugs in mania: a controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry 1975;32:34-42
21. Cookson J, Silverstone T, Wells B. Double-blind comparative clinical trial of pimozide and chlorpromazine in mania: a test of the dopamine hypothesis. Acta Psychiatr Scand 1981;64:381-397
22. Janicak PG, Brenahan DB, Sharma R, et al. A comparison of thiothixene with chlorpromazine in the treatment of mania. J Clin Psychopharmacol 1988;8:33-37
23. Brown D, Silverstone T, Cookson B. Carbamazepine compared to haloperidol in acute mania. Int Clin Psychopharmacol 1989;4:229-238
24. Barbini B, Scheerillo P, Benedetti F, et al. Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol 1997;12:109-112
25. Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998;21:176-180
26. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999;156:702-709
27. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000;57:841-849
28. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159:1011-1017
29. Yatham LN, Grossman F, Augustyns I, et al. Mood stabilizers plus risperidone or placebo in the treatment of acute mania: international, double-blind, randomized controlled trial. Br J Psychiatry 2003;182:141-147
30. Sanger TM, Tohen M, Vieta E, et al. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord 2003;73:155-161
31. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741-748
32. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-1658
33. Hirschfeld RMA, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004;161:1057-1065
34. Sachs G, Chengappa KNR, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6:213-223
35. Janenawasin S, Wang PW, Lembke A, et al. Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders. Bipolar Disord 2002;4:328-334
36. Baker RW, Tohen M, Fawcett J, et al. Acute dysphoric mania: treatment response to olanzapine versus placebo. J Clin Psychopharmacol 2003;23:132-137
37. Vieta E, Goikolea JM, Corbella B, et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry 2001;62:818-825
38. Gonzalez-Pinto A, Tohen M, Lalaguna B, et al. Treatment of bipolar I rapid cycling patients during dysphoric mania with olanzapine. J Clin Psychopharmacol 2002;22:450-454
39. Sanger TM, Grundy SL, Gibson PJ, et al. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry 2001;62:273-281
40. Vieta E, Herraiz M, Parramon G, et al. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. J Affect Disord 2002;72:15-19
41. Vieta E, Gasto C, Colom F, et al. Role of risperidone in bipolar II: an open 6-month study. J Affect Disord 2001;67:213-219
42. Brown ES, Nejtek VA, Perantie DC, et al. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord 2002;4:406-411
43. Tohen M, Chengappa KNR, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62-69
44. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218-1226
45. Tohen M, Vieta E, Calabrese JR, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar depression. Arch Gen Psychiatry 2003;60:1079-1088
46. Calabrese JR, Macfadden W, McCoy R, et al. Double-blind, placebo-controlled study of quetiapine in bipolar depression. Am J Psychiatry 2005;162:1351-1360
47. Tohen M, Bowden C, Calabrese J, et al. Olanzapine's efficacy for relapse prevention in bipolar disorder: a randomized double-blind placebo-controlled 12-month clinical trial. Eur Neuropsychopharmacol 2003;13(suppl4):S212-S213
48. Tohen M, Chengappa KNR, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilizer v mood stabilizer alone. Br J Psychiatry 2004;184:337-345
49. Brotman MA, Fergus EL, Post RM, et al. High exposure to neuroleptics in bipolar patients: a retrospective review. J Clin Psychiatry 2000;61:68-72
50. Tohen M, Zhang F, Taylor CC, et al. A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord 2001;65:85-93
51. Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic-depressive illness: a comparison with lithium. Acta Psychiatr Scand 1981;64:226-237
52. Esparon J, Kolloori J, Naylor GJ, et al. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986;148:723-725
53. Zarate CA, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted mania patients. Am J Psychiatry 2004;161:169-171
54. Sanger TM, Tohen M, Vieta E, et al. Olanzapine in the treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord 2003;73:155-161
55. Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999;156:1164-1169
56. Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63:1148-1155
57. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160:1263-1271
58. Altamura AC, Salvadori D, Madaro D, et al. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study. J Affect Disord 2003;76:267-271
59. Vieta E, Parramon G, Padrell E, et al. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 2002;4:335-340
60. Vieta E, Goikolea JM, Olivares JM, et al. 1-year follow-up of patients treated with risperidone and topiramate for a manic episode. J Clin Psychiatry 2003;64:834-839
61. Yatham LN, Binder C, Riccardelli R, et al. Risperidone in acute and continuation treatment of mania. Int Clin Psychopharmacol 2003;18:227-235
62. Vieta E, Brugue E, Goikolea JM, et al. Acute and continuation risperidone monotherapy in mania. Hum Psychopharmacol 2004;19:41-45
63. Yatham LN, Binder C, Kusumakar V, et al. Risperidone plus lithium versus risperidone plus valproate in acute and continuation treatment of mania. Int Clin Psychopharmacol 2004;19:103-109
64. Bowden CL, Myers JE, Grossman F, et al. Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. J Clin Psychiatry 2004;65:707-714
65. Cohen LS. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Erlbaum; 1988
66. Mallinckrodt CH, Clark SW, Carroll RJ, et al. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat 2003;13:179-190
67. Keck PE Jr, Corya SA, Andersen SW, et al. Olanzapine/fluoxetine combination use in rapid-cycling bipolar depression. In: New Research Program and Abstracts of the 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif. Abstract NR476
68. Kukopulos A, Reginaldi D, Laddomada P, et al. Course of the manic-depressive cycle and changes caused by treatments. Pharmakopsychiatr Neuropsychopharmakol 1980;13:156-167
69. White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993;8:119-122
70. Vieta E, Mullen J, Brecher M, et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomized, placebo-controlled studies. Curr Med Res Opin 2005;21:923-934
71. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60
72. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizer for treatment-resistant bipolar depression. Am J Psychiatry 2004;161:564-566
73. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-393
74. Post RM, Jimerson DC, Bunney WE Jr, et al. Dopamine and mania: behavioral and biochemical effects of the dopamine receptor blocker pimozide. Psychopharmacology (Berl) 1980;67:297-305
75. Hertel P, Nomikos GG, Iurlo M, et al. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (Berl) 1996;124:74-86
76. Westerink BH, de Boer P, de Vries JB, et al. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol 1998;361:27-33
77. Westerink BH, Kawahara Y, De Boer P, et al. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol 2001;412:127-138
78. Denys D, Klompmakers AA, Westenberg HG. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berl) 2004;176:195-203